KR101855206B1 - Cosmetic Composition Comprising the Fermented Extract of Panax ginseng - Google Patents
Cosmetic Composition Comprising the Fermented Extract of Panax ginseng Download PDFInfo
- Publication number
- KR101855206B1 KR101855206B1 KR1020160034639A KR20160034639A KR101855206B1 KR 101855206 B1 KR101855206 B1 KR 101855206B1 KR 1020160034639 A KR1020160034639 A KR 1020160034639A KR 20160034639 A KR20160034639 A KR 20160034639A KR 101855206 B1 KR101855206 B1 KR 101855206B1
- Authority
- KR
- South Korea
- Prior art keywords
- fermentation broth
- ginseng
- cosmetic composition
- present
- camellia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 239000002537 cosmetic Substances 0.000 title claims abstract description 46
- 235000008434 ginseng Nutrition 0.000 title abstract description 45
- 240000004371 Panax ginseng Species 0.000 title description 47
- 235000002789 Panax ginseng Nutrition 0.000 title description 2
- 238000000855 fermentation Methods 0.000 claims abstract description 85
- 230000004151 fermentation Effects 0.000 claims abstract description 85
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 30
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 30
- 235000018597 common camellia Nutrition 0.000 claims abstract description 26
- 240000001548 Camellia japonica Species 0.000 claims abstract description 25
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229930182494 ginsenoside Natural products 0.000 claims 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 43
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 29
- 238000004519 manufacturing process Methods 0.000 abstract description 21
- 230000015572 biosynthetic process Effects 0.000 abstract description 17
- 230000037303 wrinkles Effects 0.000 abstract description 15
- 230000032683 aging Effects 0.000 abstract description 12
- 230000003020 moisturizing effect Effects 0.000 abstract description 12
- 108010035532 Collagen Proteins 0.000 abstract description 10
- 102000008186 Collagen Human genes 0.000 abstract description 10
- 229920001436 collagen Polymers 0.000 abstract description 10
- 244000063299 Bacillus subtilis Species 0.000 abstract description 8
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- 230000002087 whitening effect Effects 0.000 abstract description 8
- 235000017803 cinnamon Nutrition 0.000 abstract description 7
- 210000004927 skin cell Anatomy 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 102000029816 Collagenase Human genes 0.000 abstract description 3
- 108060005980 Collagenase Proteins 0.000 abstract description 3
- 229960002424 collagenase Drugs 0.000 abstract description 3
- 206010052428 Wound Diseases 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 abstract 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 62
- 230000000052 comparative effect Effects 0.000 description 56
- 238000002360 preparation method Methods 0.000 description 51
- 238000009472 formulation Methods 0.000 description 50
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 40
- 239000004310 lactic acid Substances 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 32
- 235000014655 lactic acid Nutrition 0.000 description 31
- 241000894006 Bacteria Species 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 21
- 239000000243 solution Substances 0.000 description 17
- 239000002609 medium Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 241000193830 Bacillus <bacterium> Species 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- -1 tracant Substances 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 230000037394 skin elasticity Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 8
- 241000723346 Cinnamomum camphora Species 0.000 description 8
- 229960000846 camphor Drugs 0.000 description 8
- 229930008380 camphor Natural products 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000723347 Cinnamomum Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 230000008099 melanin synthesis Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 240000008397 Ganoderma lucidum Species 0.000 description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002780 melanosome Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000544912 Melanoides Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000005016 dendritic process Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 순차 발효시킨 장뇌삼 발효액을 포함하는 화장료 조성물에 관한 것이다. 바람직하게는 상기 장뇌삼 발효액은 장뇌삼을 바실러스속 균주(Bacillus subtilis) 또는 효모(Saccharomyces cerevisiae)로 배양하여 얻은 1차 발효액을 유산균 균주 Lactobacillus plantarum)를 이용하여 2차 발효하여 얻은 것이다. 본 발명의 장뇌삼 발효액은 피부 세포 활성을 증진시키고, 콜라겐 등의 피부 세포 단백질의 합성을 촉진시켜 주며, 콜라겐 분해 효소의 생성을 억제해줌으로써 노화로 인해 발생하는 피부 주름 개선 및 탄련 개선 효능을 갖고 있다. 또한 본 발명의 장뇌삼 발효액은 보습 및 미백효능을 가지고 있다. The present invention relates to a cosmetic composition comprising a fermentation broth of cinnamon germ fermented successively. Preferably, the camellia fermentation broth is obtained by secondary fermentation using a primary fermentation broth obtained by cultivating camellia ginseng as a Bacillus subtilis or a yeast (Saccharomyces cerevisiae) using Lactobacillus plantarum. The camellia fermentation broth of the present invention promotes skin cell activity, promotes the synthesis of skin cell proteins such as collagen, inhibits the production of collagenase, thereby improving wrinkles and wounds caused by aging . The ginseng fermentation broth of the present invention has moisturizing and whitening effect.
Description
본 발명은 장뇌삼 발효액을 포함하는 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition comprising a ginseng fermentation broth.
사람의 피부는 노화 과정에서 다양한 물리·화학적인 변화가 일어난다. 그 원인으로는 크게 내적인 노화 (intrinsic aging)와 광노화 (photo-aging)로 구분되며 이에 관한 연구가 활발히 이루어져 왔다. 자외선, 스트레스, 질병 상태, 환경 인자, 상처, 나이가 들어감에 따라 자유라디칼이 활성화되어 야기될 수 있으며, 이런 상태가 심화될 경우 생체 내에 존재하는 항산화 방어망을 파괴하고, 세포 및 조직을 손상시켜 성인병 및 노화를 촉진하게 된다. A variety of physical and chemical changes occur in human skin during the aging process. The cause of this phenomenon is divided into intrinsic aging and photo-aging. Free radicals can be caused by activation of ultraviolet rays, stress, disease state, environmental factors, wounds, and aging. When such state is deepened, the antioxidant defense network existing in the living body is destroyed, And aging.
좀 더 구체적으로 말하자면, 피부의 주요 구성 물질인 지질, 단백질, 다당류 및 핵산 등이 산화되어 피부 세포 및 조직이 파괴되고, 결국 피부 노화 현상이 생겨나는 것이다. 특히, 단백질의 산화는 피부의 결합 조직인 콜라겐 (collagen), 히아루론산 (hyaluronic acid), 엘라스틴 (elastin), 프로테오글리칸 (proteoglycan), 피브로넥틴 (fibronectin) 등이 절단되어 심한 과다 염증 반응과 피부의 탄력에 지장을 주고 이것이 더 심해질 경우 DNA의 변이에 의해 돌연변이, 암의 유발, 면역 기능 저하의 사태에 이르게 된다. More specifically, lipids, proteins, polysaccharides and nucleic acids, which are major components of the skin, are oxidized to destroy skin cells and tissues, resulting in skin aging. In particular, the oxidation of proteins can cause collagen (collagen), hyaluronic acid, elastin, proteoglycan, fibronectin, and the like that are severely hyperinflammatory reaction and skin elasticity If this gets worse, DNA mutations can lead to mutations, cancer, and immune deficiency.
그러므로 신체의 대사 과정 중 발생하는 자유라디칼이나 자외선 조사, 염증 반응에 의해 매개되어 발생하는 자유라디칼을 소거하여 세포막을 보호하고, 또 이미 손상 받은 세포는 활발한 신진 대사에 의해 재생시켜서 세포를 증식시켜야 피부는 빠르게 회복되고 건강한 피부를 유지할 수 있다. Therefore, it is necessary to protect the cell membrane by destroying the free radicals mediated by free radicals, ultraviolet rays, and inflammation that occur during the metabolism of the body, and to regenerate already damaged cells by active metabolism, Can quickly recover and maintain healthy skin.
노화에는 이러한 자유라디칼 뿐만 아니라 콜라겐 분해효소인 기질 금속 단백질 분해 효소 (Matrix Metalloproteinase; MMP)라는 효소도 관여한다. 즉, 생체 내에서 콜라겐과 같은 세포외기질의 합성과 분해는 적절하게 조절되나, 노화가 진행되면서 콜라겐 합성이 감소하고, 콜라겐을 분해하는 효소인 기질 금속 단백질 분해 효소(MMP)의 발현이 촉진되어 피부의 탄력이 저하되고 주름이 형성된다. 또한, 자외선 조사에 의해 이러한 분해 효소가 활성화되기도 한다. Aging involves not only these free radicals, but also enzyme called matrix metalloproteinase (MMP), a collagenase. That is, synthesis and degradation of extracellular matrix such as collagen in vivo are appropriately controlled, but collagen synthesis is reduced as aging progresses, and expression of matrix metalloproteinase (MMP), an enzyme that degrades collagen, is promoted, And the wrinkles are formed. These degrading enzymes are also activated by ultraviolet irradiation.
그러므로, 세포 내에서 활성화가 유도되는 MMP 발현을 조절하거나 그 활성을 억제할 수 있는 물질의 개발이 요구되고 있다. 이제까지 화장품의 소재로서 사용된 원료들은 단순히 효소 활성만을 억제하는 것이 대부분이었다. 이에 세포내 자연노화와 광노화에 의해 그 발현이 유도되는 MMP 발현량 및 활성을 조절하고자 하였다. Therefore, there is a demand for development of a substance capable of modulating MMP expression induced in the cell or inhibiting its activity. Until now, the raw materials used as cosmetic materials mostly inhibited only the enzyme activity. Therefore, we tried to control the amount and activity of MMP expression induced by intracellular natural aging and photoaging.
한편, 색소 침착에 의한 피부 변화가 생긴다. 피부색을 결정하는 인자에는 기본적으로 인종과 지역, 성별, 나이에 따른 차이를 배제하면 기미, 주근깨와 자외선 노출로 인한 태닝과 같은, 부분 또는 전체적인 색소 침착, 그 외에 여드름 및 흉터, 각질의 분포 상태와 혈액 순환, 스트레스, 건강 상태 등이 있다. 이상의 인자들 가운데에서도 가장 중요한 인자는 색소 침착이다. On the other hand, skin changes due to pigment deposition occur. The factors that determine skin color are basically the partial or total pigmentation such as stain, freckle and tanning due to ultraviolet exposure, and the distribution of acne and scars and keratin Blood circulation, stress, and health. The most important factor among these factors is pigmentation.
피부색에 영향을 주는 색소로는 멜라닌, 멜라노이드, 카로틴, 헤모글로빈 등이 있는데, 이중 가장 중요한 것은 멜라닌으로서, 이 멜라닌의 생합성에 영향을 미치는 가장 큰 요인은 자외선과 체내 호르몬 분비 정도이다. Melanin, melanoid, carotene and hemoglobin are the most important factors affecting skin color. Among them, melanin is the most important factor affecting the biosynthesis of melanin.
멜라닌은 자외선을 흡수 또는 산란시켜 자외선으로부터 피부가 손상되는 것을 방지하는데 큰 역할을 하는데, 특별한 최대 흡수 파장이 없고 전 영역의 빛을 흡수한다. 또한 활성 산소종을 제거하는 기능이 탁월하나, 때로는 멜라닌 자체가 활성 산소를 발생시키기도 하며, 멜라닌 구조 내의 카테콜이나 퀴논에 의하여 다른 물질을 환원시키거나 산화시키고, 멜라닌 자체가 자유라디칼의 성질을 나타내기도 한다. Melanin absorbs or scatters ultraviolet light and plays a major role in preventing damage to the skin from ultraviolet rays. It does not have a specific maximum absorption wavelength and absorbs light in all areas. In addition, it has excellent ability to remove reactive oxygen species, sometimes melanin itself generates active oxygen, and other substances are reduced or oxidized by catechol or quinone in the melanin structure, and melanin itself shows free radical properties Pray.
멜라닌의 생합성은 아미노산의 일종인 티로신이 멜라닌 형성 세포의 멜라노좀에서 티로시나제에 의해 산화되어 디하이드록시 페닐알라닌 (dihydroxy phenylalanine)으로 전환되는 것을 시작으로 계속되는 일련의 산화 과정을 거쳐 갈색 (pheomelanin), 흑색 (eumelanin)의 중합체로 형성된다. The biosynthesis of melanin begins with the conversion of tyrosine, an amino acid, into melanosomes of melanocyte-forming melanosomes by tyrosinase and conversion to dihydroxy phenylalanine, followed by a series of oxidation processes to form pheomelanin, eumelanin.
이러한 생합성 과정은 멜라노좀이라는 특수한 형태의 갈색 세포 내 소기관에서 진행되며 멜라닌 과립을 포함한 멜라노좀은 핵 주변 부위에서 수지상 돌기 끝부분으로 이동, 각질 세포의 식세포 작용에 의해 세포질 내로 이동하고 이들은 각질 세포의 핵 주변에 축적된다. This biosynthesis process is carried out in a special form of melanocyte in the brown intracellular organelle. The melanomas, including melanin granules, migrate from the nucleus to the tip of the dendritic process, and migrate into the cytoplasm by phagocytosis of keratinocytes. It accumulates around the nucleus.
멜라닌의 합성과 멜라노좀의 수, 주위의 각질 세포로의 이동은 부분적으로 호르몬과 자외선 등에 영향을 받고 일차적으로는 유전적인 영향을 크게 받는다. 그 밖에 티로시나제의 발현 및 멜라닌의 합성, 전송에 관여하는 세포내 조절인자인 싸이토카인 (cytokine), 구리, 아연, 철 등의 금속 이온 및 인터페론, 프로스타글란딘, 히스타민 등이 관여하는 것으로 알려져 있다. The synthesis of melanin, the number of melanosomes, and the migration to keratinocytes in the periphery are partially affected by hormones and ultraviolet rays, and are primarily affected by genetics. In addition, it is known that interleukins, prostaglandins, histamines, and the like are involved in the expression of tyrosinase and cytokine, which is an intracellular regulator involved in the synthesis and transmission of melanin, and metal ions such as copper, zinc and iron.
이미 아스코르빈산(일본특개평 4-9320), 하이드로퀴논(일본특개평-192062), 코직산(일본특개소 56-7710), 알부틴(일본특개평 4-93150) 및 일부의 추출물 등이 티로시나제 저해 활성을 가지고 있어 미백 화장료로 이용되고 있다. 하지만, 이들은 화장품 제형 중에서의 안정성이 낮으므로 분해되어 착색되거나, 이취의 발생, 생체 레벨에서의 효능, 효과의 불분명 및 안전성 문제 등으로 그 사용이 제한되고 있는 실정이다. 그리고 상기한 물질들은 그 티로시나제 억제 효과가 입증되었으나 실제 생체 레벨과 유사한 실험에서는 그 효과가 낮게 나타난다. 따라서 생체 레벨과 유사한 흑색종 세포 배양에 의한 저해효과 평가가 요구되고 있는 실정이다. 또한, 하이드로퀴논은 발암성 물질로 규정되어 화장품에서는 그 사용이 금지 또는 제한되고 있다. 코직산과 아스코르빈산은 매우 불안정한 물질이다. 상기 성분들을 소량 함유한 화장료는 실온에서 수 주 동안 보관하면 갈변 현상이 발생한다. (Japanese Patent Laid-open No. 4-9320), hydroquinone (Japanese Patent Laid-Open No. 192062), kojic acid (Japanese Patent Laid-open No. 56-7710), arbutin And has been used as a whitening cosmetic. However, since they are low in stability in cosmetic formulations, their use is limited due to their decomposition and coloring, the generation of odor, the efficacy at the living body level, the uncertainty of the effect, and the safety problem. These substances have proved their tyrosinase inhibitory effect, but their effect is lower in experiments similar to actual living body level. Therefore, it is required to evaluate the inhibitory effect by the melanoma cell culture similar to the biological level. Hydroquinone is also defined as a carcinogenic substance and its use in cosmetics is prohibited or restricted. Kojic acid and ascorbic acid are very unstable substances. When a cosmetic containing a small amount of the above components is stored at room temperature for several weeks, browning occurs.
이러한 여러 가지 문제점을 해결하기 위하여, 최근 여러 화학 물질 등에 의한 피부 자극을 줄이기 위해 천연물을 사용한 화장품이 많이 개발되고 있다. 천연 재료는 피부에 부작용이 적을 뿐만 아니라, 최근 천연 재료를 이용한 화장품에 대한 소비자들의 호응이 높아짐에 따라 화장품 원료로서 개발 가치가 한층 늘어나고 있다. In order to solve these various problems, recently, many cosmetics using natural products have been developed to reduce skin irritation caused by various chemical substances and the like. Natural materials are not only less harmful to the skin, but also have increased their value as a raw material for cosmetics due to the recent popularity of cosmetics using natural materials.
본 발명자들은 노화로 인해 손상된 다양한 피부 트러블들을 해결하기 위하여 예의 노력한 결과, 장뇌삼을 바실러스속 미생물 또는 효모균을 이용하여 발효시킨 1차발효액을 유산균을 이용하여 2차 발효한 발효액이 피부 노화로 인해 발생하는 피부의 문제점, 특히 피부 주름을 효과적으로 개선할 수 있음을 확인함으로써 본 발명을 완성하였다. 따라서, 본 발명은 피부 주름 개선효과가 뛰어난 화장료 조성물을 제공하는 것을 목적으로 한다. 또한, 피부 탄력 개선, 보습, 미백 효과를 갖는 화장료 조성물을 제공하는 것을 목적으로 한다.As a result of intensive efforts to solve various skin troubles damaged by aging, the inventors of the present invention have found that when a primary fermentation broth fermented with Bacillus subtilis microorganism or yeast bacterium is used as a fermentation solution secondary fermented with lactic acid bacteria, The present inventors have completed the present invention by confirming that the problems of the skin, particularly the skin wrinkles, can be effectively improved. Accordingly, it is an object of the present invention to provide a cosmetic composition having an excellent skin wrinkle-reducing effect. It is another object of the present invention to provide a cosmetic composition having skin elasticity improvement, moisturizing and whitening effect.
상기한 과제는 순차 발효시킨 장뇌삼 발효액을 유효성분으로 함유하는 화장료 조성물에 의해 달성된다.The above-mentioned problem is attained by a cosmetic composition comprising an effective fermentation solution of camellia seeds which has been continuously fermented.
바람직하게는, 상기 장뇌삼 발효액은 장뇌삼을 바실러스속 균주 또는 효모를 이용하여 1차 발효하고, 상기 1차 발효액을 비피더스(Bifidus)균 및 불가리스(Bulgaricus)균, 락토바실러스(Lactobacillus)로 이루어진 군에서 선택된 1종의 유산균 균주를 이용하여 2차 발효하여 수득한 바실러스-유산균 발효액 또는 효모-유산균 발효액일 수 있다. Preferably, the camellia fermentation broth is a fermentation broth comprising primary fermentation of camellia ginseng with a strain of Bacillus subtilis or yeast, wherein the primary fermentation broth is selected from the group consisting of Bifidus bacteria, Bulgarian bacterium, Lactobacillus It may be a fermentation liquid of bacillus-lactic acid bacteria or a yeast-lactic acid fermentation broth obtained by secondary fermentation using one kind of lactic acid bacteria strain.
또한 바람직하게는, 상기 바실러스속 균주는 바실러스 서브틸리스(Bacillus subtilis)이고, 상기 효모는 사카로마이세스 세레비시애(Saccharomyces cerevisiae)일 수 있다.Also preferably, the strain of Bacillus subtilis is Bacillus subtilis, and the yeast may be Saccharomyces cerevisiae.
또한, 상기 화장료 조성물은 피부 주름 개선, 피부 탄력 개선, 보습 또는 미백 효과를 갖는다. In addition, the cosmetic composition has an effect of improving skin wrinkles, improving skin elasticity, moisturizing or whitening.
바람직하게는 상기 장뇌삼 발효액은 화장료 조성물 총 중량에 대하여 0.0001-30.0%(w/w)로 함유될 수 있다. Preferably, the camellia fermentation broth may be contained in an amount of 0.0001-30.0% (w / w) based on the total weight of the cosmetic composition.
본 발명 화장료 조성물은 유효성분으로서 장뇌삼 발효액을 포함하며, 상기 장뇌삼 발효액은 장뇌삼을 효모-유산균 발효액 또는 바실러스-유산균 발효액으로서, 세포 활성 및 콜라겐 합성을 촉진해주며, 자외선등에 의해 생성이 증가되는 콜라겐 분해 효소(MMP-1)의 생합성을 효과적으로 억제하여 주는 효과를 갖는다. 또한, 본 발명에 따른 장뇌삼 발효액은 외부 자극에 의한 피부 세포 자극을 완화해 주고 피부를 밝게 하며, 피부 보습 효과를 갖는다. The cosmetic composition of the present invention comprises a tea germ extract as an active ingredient and the ginseng fermentation broth is a fermentation broth of yeast-lactic acid fermentation broth or a bacterium-lactic acid bacterium which promotes cellular activity and collagen synthesis, It has an effect of effectively inhibiting the biosynthesis of the enzyme (MMP-1). The ginseng fermentation broth according to the present invention alleviates skin cell stimulation by external stimulation, brightens skin, and has a skin moisturizing effect.
상기 목적을 달성하기 위해, 본 발명은 장뇌삼 발효액을 포함하는 피부 주름 개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for improving skin wrinkles comprising a ginseng fermentation broth.
본 발명에서 장뇌삼(Panax Ginseng)은 산삼의 일종으로서, 산삼은 크게 천종, 지종 및 장뇌(인종) 3종류로 분류되며, 천종은 천연 산삼으로 조류가 종자를 먹은 뒤 산속에 배설하여 자생한 것, 지종은 천종의 씨앗이 주위에 떨어져 자생한 것, 그리고 장뇌삼은 산삼의 종자를 채취하여 깊은 산속에 씨를 뿌려 야생 상태로 인위적으로 재배한 산삼을 가리킨다. 이러한 산삼 중에서 비교적 구입이 용이한 장뇌삼은 인삼에 비하여 주성분인 사포닌이 더 많고 약리 효능이 더 높다고 알려져 있다. 장뇌삼의 공지된 약리학적 효능은 당뇨, 간질환, 고혈압, 부인병 및 갱년기 증상의 치료이다.In the present invention, Panax Ginseng is a kind of wild ginseng, and the wild ginseng is classified into three kinds of ginseng, geomorphic, and camphor (racial). The ginseng is natural wild ginseng, which algae excrete in the mountains after eating seeds, The seeds of a thousand species have fallen around, and the ginseng ginseng refers to wild ginseng that has been cultivated in a wild state by artificially sowing the seeds of the wild ginseng in deep mountains. Among these wild ginsengs, it is known that the relatively easy to purchase ginseng extract has higher saponin and pharmacological effect than the ginseng. The known pharmacological efficacy of camphor ginseng is the treatment of diabetes, liver disease, hypertension, gynecological diseases and menopausal symptoms.
한편, 본 명세서에서 용어 “장뇌삼”은 장뇌삼의 다양한 기관(예: 잎, 열매, 꽃, 줄기 및 뿌리 등)을 의미하며, 바람직하게는 장뇌삼의 뿌리를 의미한다.In the present specification, the term " camellia ginseng " refers to various organs (e.g., leaves, fruits, flowers, stems and roots) of camphor ginseng, and preferably means roots of camphor ginseng.
본 명세서에서 용어 "순차 발효시킨 장뇌삼 발효액"은 바실러스속 균주(Bacillus sp)를 이용하여 발효한 1차 발효액에 유산균 균주를 배양하여 2차 발효한 바실러스-유산균 발효액, 또는 효모를 이용하여 발효한 1차 발효액에 유산균 균주를 배양하여 2차 발효한 효모-유산균 발효액을 가리킨다.As used herein, the term " camellia fermentation broth obtained by sequential fermentation "refers to a fermented bacillus-lactic acid fermentation broth obtained by culturing a lactic acid bacterium strain in a primary fermentation broth fermented using a Bacillus sp. Strain or fermented with yeast Refers to a yeast-lactic acid fermentation broth obtained by cultivating a lactic acid bacterium strain in a second fermentation broth.
본 발명에서, 바실러스 균주는 그람양성의 미생물이며, 내생포자 형성이 가능하고, 장간균(rod shape)의 형태를 가지고 있다. 본 발명의 장뇌삼을 1차 발효시키는데 유용한 바실러스 균주는 바실러스 서브틸리스(Bacillus subtilis)이다.In the present invention, the Bacillus strain is a Gram-positive microorganism, capable of endogenous spore formation, and has a rod shape. The Bacillus strain useful for primary fermentation of camellia ginseng is Bacillus subtilis.
또한, 본 발명의 효모균은 진핵미생물(핵과 세포질이 핵막에 의하여 나누어져 있는 생물)에 속하며 세포벽, 세포막, 핵, 사립체, 과립 등 세포 소기관을 갖추고 있다. 성의 구별이 없는 이들은 주로 budding(출아법)으로 번식하는데, 분리된 많은 효모들 중에는 발효능이 없는 것, budding 대신 fission(분열) 혹은 bud-fission 방법으로 증식하는 것, ascospore(자낭포자)가 아닌 ballistospore를 형성하거나 spore(포자)형성이 관찰되지 않는 것 등 다양한 그룹의 효모도 존재한다. 크기는 보통 5-10×5-12㎛로 세균의 5-10배 크기이며, 적정 pH는 4.5 내지 5.5이나 1 내지 10에서도 생존한다. pH 1에서 12시간 생존하는 효모는 박테리아보다 산에 강하므로 배지의 pH를 3.5 내지 3.8 정도로 맞추면 박테리아의 오염을 어느 정도 억제할 수 있다.In addition, the yeast of the present invention belongs to a eukaryotic microorganism (a nuclear and cytoplasmic organism separated by a nuclear membrane) and has cell organelles such as a cell wall, a cell membrane, a nucleus, a mitochondria, and a granule. Those with no distinction of sex mainly reproduce by budding. Among many separated yeasts, there is no efficacy, fission instead of budding or bud-fission, ballistospore, not ascospore, Or spores (spores) are not observed in the yeast. The size is usually 5 -10 × 5 -12 μm, 5 -10 times the size of bacteria, and the optimum pH is 4.5 to 5.5 or 1 to 10 survivors. Yeast surviving at pH 1 for 12 hours is stronger in acid than in bacteria, so if the pH of the medium is adjusted to about 3.5 to 3.8, bacterial contamination can be suppressed to some extent.
효모는 균 종에 따라서 조금씩 차이가 있으나, 대부분 20~30℃에서 잘 자란다. 보통은 50℃ 이상에서는 효모가 사멸한다고 하지만, 그 온도 이상에서 합성이 되지 않는 성장요소를 배지에 직접 첨가해 줌으로서 어느 정도 극복이 가능하다. 사카로마이세스 세레비시애(Saccharomyces cerevisiae)의 경우, 40℃ 이상에서 사멸하지만, 배지에 올레익산(oleic acid)과 에르고스테롤(ergosterol)을 첨가해 줌으로서 이를 방지할 수 있다. 효모 균체 자체는 단세포 식물로서 단백질과 미량광물질을 다량 함유하고 있다.Yeast is slightly different depending on species, but most of them grow well at 20 ~ 30 ℃. It is usually said that yeast is killed at temperatures above 50 ° C, but it can be overcome to some extent by adding growth factors that are not synthesized above that temperature, directly to the medium. In the case of Saccharomyces cerevisiae, it can be prevented by adding oleic acid and ergosterol to the medium at a temperature of 40 ° C. or higher. Yeast cells themselves are unicellular plants and contain large amounts of proteins and trace minerals.
본 발명의 장뇌삼을 1차 발효시키는데 유용한 효모는 사카로마이세스 세레비시애(Saccharomyces cerevisiae)이다. The yeast useful for primary fermentation of camellia seeds of the present invention is Saccharomyces cerevisiae.
본 발명에서 2차 발효에 사용되는 유산균 균주는 당을 발효시켜 유산을 생성하는 간균으로 그람 양성을 나타내며 포자(胞子)를 가지지 않으며 미호기성(微好氣性) 또는 혐기성이다. 유산균에는 유산균 음료 제조에 유용한 아시도필러스균, 모유영양아(母乳營養兒)의 장에 많이 서식하는 비피더스스균, 불가리아유(乳)라 불리는 발효물을 만드는 불가리아균 등이 있다. .In the present invention, the lactic acid bacteria strain used in the second fermentation is a bacterium that produces lactic acid by fermenting sugars and is gram-positive, does not have spores, and is micro-aerobic or anaerobic. Lactic acid bacteria include acidophilus, which is useful for the production of lactic acid bacteria, bifidus bacteria which live in the field of breastfed babies, and bacteria which make fermented products called Bulgarian milk. .
본 발명의 장뇌삼을 2차 발효시키는데 유용한 유산균는 락토바실러스 플란타룸(Lactobacillus plantarum)이다. The lactic acid bacterium useful for secondary fermentation of the camellia ginseng according to the present invention is Lactobacillus plantarum.
본 발명에서, 순차 발효시킨 장뇌삼 발효액은 다음의 단계를 포함하는 방법으로 제조될 수 있다:In the present invention, the successively fermented camellia fermentation broth can be prepared by a method comprising the following steps:
a) 장뇌삼 분말을 100 내지 500 메쉬를 이용하여 미세하게 만드는 단계;a) finely dividing the ginseng ginseng powder using 100 to 500 mesh;
b) 상기 단계 a)에서 제조한 장뇌삼 분말을 통상적인 미생물 배양액에 1 내지 50 g/L 첨가하고, 바실러스 균주 또는 효모를 10,000 내지 100,000 cfu/L의 양으로 첨가하는 단계;b) adding 1 to 50 g / L of the camphor ginseng powder prepared in step a) to a conventional microorganism culture solution, adding Bacillus strains or yeasts in an amount of 10,000 to 100,000 cfu / L;
c) 상기 단계 b)의 배양물을 30 ~ 37℃에서, pH 5 ~ 7로 호기적 또는 통성 혐기적인 조건으로 약 5 내지 10 일간 배양하는 단계;c) culturing the culture of step b) at 30 to 37 DEG C for 5 to 10 days under aerobic or anaerobic conditions at a pH of 5 to 7;
d) 단계 c)의 배양액을 80℃ ~ 85℃에서 진공 멸균하는 단계; d) vacuum sterilizing the culture of step c) at 80 ° C to 85 ° C;
e) 상기 단계 d)의 멸균 배양액을 여과한 후 5 내지 10일 동안 저온 숙성시켜 여과하는 단계;e) filtering the sterilized culture solution of step d), aging the solution at low temperature for 5 to 10 days and filtering;
f) 상기 단계 e)의 여과액을 동결건조하여 파우더를 얻는 단계;f) lyophilizing the filtrate of step e) to obtain a powder;
g) 유산균 배지에 락토바실러스 균주를 100,000 내지 1,000,000 cfu/L의 양으로 첨가하는 단계; g) adding lactobacillus strain to the lactic acid bacteria medium in an amount of 100,000 to 1,000,000 cfu / L;
h) 상기 단계 g)의 유산균 배지에 상기 단계 f)의 발효액 파우더를 1 내지 30 g/L 첨가하고 30 ~ 37℃에서, pH 3 ~ 6으로 미호기적 또는 혐기적인 조건으로 약 5 내지 10일간 배양하는 단계;h) 1 to 30 g / L of the fermentation broth of step f) is added to the lactic acid bacterium culture of step g) and cultured at 30 to 37 DEG C for 3 to 6 days at pH 3-6 for 5 to 10 days under mooring or anaerobic conditions ;
i) 상기 단계 h)의 배양액을 80℃ ~ 85℃에서 진공 멸균하는 단계;i) vacuum sterilizing the culture of step h) at 80 ° C to 85 ° C;
j) 상기 단계 i)의 멸균 배양액을 여과한 후 5 내지 10일 동안 저온 숙성시켜 여과하는 단계;j) filtering the sterilized culture solution of step i), aging the solution at low temperature for 5 to 10 days, and filtering;
k) 동결건조하여 장뇌삼 발효액 파우더를 얻는 단계.k) lyophilization to obtain a ginseng fermentation broth powder.
본 발명의 바람직한 구현예에 따르면 본 발명에서 사용한 장뇌삼 발효액은 다음과 같이 하여 얻었다:According to a preferred embodiment of the present invention, the ginseng fermentation broth used in the present invention was obtained as follows:
장뇌삼 분말을 300메쉬로 분말화 한 뒤 배양액에 10 g/L 첨가하고, 바실러스 균주 또는 효모 균주를 500,000 cfu/L로 첨가하여 30 ~ 37℃에서, pH 5-7로 호기적 또는 통성 혐기적인 조건으로 발효조에서 약 7일간 배양한다. 배양 후 얻은 배양액을 85°C에서 진공멸균한 뒤 0.25μM의 여과지를 이용하여 여과한 후 7일간 저온숙성하여 여과한다. 이 여액을 동결건조하여 효모발효액의 파우더를 얻고 유산균 배지에 상기 파우더를 5g/L로 첨가한 뒤, 락토바실러스 균주를 1,000,000 cfu/L로 첨가하여 30 ~ 37℃에서, pH 3 ~ 6로 미호기적 또는 혐기적인 조건으로 발효조에서 약 7일간 배양한다. 이 배양액을 85°C에서 진공멸균한 뒤 0.25μM의 여과지를 이용하여 여과한 후 7일간 저온숙성하여 여과하고 동결건조하여 장뇌삼 발효액을 얻었다. 상기 장뇌삼 발효액은 사용하기 전에 최종 고형분의 농도를 10g/L가 되게 유지하였다The ginseng powder was pulverized to 300 mesh, added with 10 g / L to the culture medium, added with 500,000 cfu / L of Bacillus strain or yeast strain and cultured at 30 ~ 37 ℃ under aerobic or tuberous anaerobic conditions And cultivated in a fermenter for about 7 days. After culturing, the resulting culture is vacuum-sterilized at 85 ° C, filtered through 0.25 μM filter paper, and aged at low temperature for 7 days. The resulting filtrate was lyophilized to obtain a powder of yeast fermentation broth. The powder was added to the lactic acid bacteria medium at a concentration of 5 g / L, and the lactobacillus strain was added at 1,000,000 cfu / L. Or anaerobic conditions in a fermenter for about 7 days. The culture was vacuum-sterilized at 85 ° C, filtered through a filter paper of 0.25 μM, aged at low temperature for 7 days, filtered and lyophilized to obtain a ginseng fermentation broth. The ginseng fermentation broth was maintained at a final solid concentration of 10 g / L before use
본 발명에서, 장뇌삼 발효액은 세포 활성을 촉진시켜 주며, 콜라겐 합성을 증진시켜 주고, 콜라겐 분해 효소의 생성을 억제하며, 보습을 개선하고, 주름을 개선하며, 피부를 밝게 해주며, 피부 자극을 완화해주는 다양한 특징을 갖고 있다. 따라서, 본 발명은 장뇌삼 발효액을 화장료에 첨가함으로써 노화로 인해 발생하는 피부 손상, 즉 피부주름, 탄력 저하, 미백 및 보습에 대해 매우 우수한 효과를 보여준다.In the present invention, the fermentation broth of Camellia sinensis promotes cell activity, promotes collagen synthesis, inhibits the production of collagenase, improves moisturization, improves wrinkles, brightens skin, alleviates skin irritation It has a variety of features. Accordingly, the present invention shows very good effects on skin damage caused by aging, i.e., skin wrinkles, reduced elasticity, whitening, and moisturizing, by adding a camellia fermentation broth to a cosmetic.
본 발명에서, 장뇌삼 발효액의 함량은 전체 화장료 조성물에 대하여 0.0001~30.0 %(w/w)이고, 보다 바람직하게는 0.001~10%(w/w)이다. 장뇌삼 발효액의 함량이 0.0001 %(w/w) 미만일 경우에는 뚜렷한 주름개선 효과, 탄력 개선효과, 보습 및 미백 효과를 기대할 수 없고, 장뇌삼 발효액의 함량이 30.0%를 초과하는 경우에는 함유량 증가에 따른 뚜렷한 효과의 증가가 나타나지 않으며, 피부자극을 유발하거나 제형의 안정성에 있어서 문제가 생긴다.In the present invention, the content of the camellia fermentation broth is 0.0001 to 30.0% (w / w), more preferably 0.001 to 10% (w / w) based on the total cosmetic composition. When the content of camellia fermentation broth is less than 0.0001% (w / w), it is not expected to have a remarkable effect of improving wrinkles, improving elasticity, moisturizing and whitening effect. When the content of camellia fermentation broth exceeds 30.0% There is no increase in the effect, and it causes skin irritation or problems in the stability of the formulation.
본 발명의 화장품 조성물에 포함되는 성분은 유효 성분으로서의 장뇌삼 발효액 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The ingredients contained in the cosmetic composition of the present invention include components commonly used in cosmetic compositions in addition to the camellia fermentation broth as an active ingredient and include conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and Carrier.
본 발명의 화장료 조성물은 당 업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어,용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수(스킨), 영양 화장수(밀크로션), 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a flexible lotion (skin), a nutritional lotion (milk lotion), a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder .
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클린징 제형은 클렌징폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.When the cosmetic composition of the present invention is a soap, a surfactant-containing cleansing agent, or a surfactant-free cleansing agent, it may be applied to the skin and then wiped off or removed or washed with water. The surfactant-containing cleansing formulation is a cleansing foam, a cleansing water, a cleansing towel, and a cleansing pack. The surfactant-free cleansing formulation may be a cleansing cream, , Cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
비교 compare 제조예Manufacturing example 1. 효모를 이용한 장뇌삼 효모 발효액 제조 1. Preparation of yeast fermentation broth using yeast
정제수로 세척하고 건조한 장뇌삼을 분말화 한 후 300메시를 이용하여 미세하게 만들었다. 이것을 10g/L되게 효모 배양액(Potato Dextrose Broth, 아큐메디아, 미합중국)에 첨가하였다. 발효에 사용한 효모 균주는 사카로마이세스 세레비시애(Saccharomyces cerevisiae)를 사용하였으며, 배양액당 500,000 cfu/L로 첨가하였다. 배양은 5L 발효조를 이용하여 7일간, 30℃, pH 5-7로 유지하며 배양하였다. 배양 후 배양액을 85℃에서 진공멸균 한 뒤 원심분리하여 배양균을 1차 제거 한 후 0.25 μM 여과지를 이용하여 최종여과 하였다. 이렇게 얻은 여과액을 다시 4℃의 저온 창고에서 약 10일간 숙성시킨 후 이 액을 다시 0.25μM의 여과기를 이용하여 여과액을 동결건조하여 '장뇌삼 효모 발효액' 분말을 얻었다. After washing with purified water and drying, the dried ginseng ginseng was pulverized and made fine using 300 mesh. This was added to a yeast culture solution (Potato Dextrose Broth, Akyumedia, USA) at 10 g / L. Saccharomyces cerevisiae was used as a yeast strain used for fermentation and added at 500,000 cfu / L per culture. The cultures were maintained at 30 ° C and pH 5-7 for 7 days using a 5L fermenter. After incubation, the culture broth was vacuum-sterilized at 85 ° C, centrifuged, and the culture was firstly removed, followed by final filtration using 0.25 μM filter paper. The filtrate thus obtained was aged at a low temperature warehouse at 4 ° C for about 10 days, and then the filtrate was freeze-dried by using a 0.25 μM filter to obtain a 'ginseng yeast fermentation broth' powder.
비교 compare 제조예Manufacturing example 2. 2. 바실러스를Bacillus 이용한 장뇌삼 Used ginseng 바실러스Bacillus 발효액 제조 Manufacture of fermentation broth
정제수로 세척하고 건조한 장뇌삼을 분말화 한 후 300메시를 이용하여 미세하게 만들었다. 이것을 10g/L되게 바실러스 배양액(Tryptic soy Broth, 아큐메디아, 미합중국)에 첨가하였다. 발효에 사용한 바실러스 균주는 바실러스 서브틸리스(Bacillus subtilis)를 사용하였으며, 배양액당 1,000,000 cfu/L로 첨가하였다. 배양은 5L 발효조를 이용하여 7일간, 37℃, pH 5-7로 유지하며 배양하였다. 배양 후 배양액을 85℃에서 진공멸균한 뒤 원심분리하여 배양균을 1차 제거 한 후 0.25 μM 여과지를 이용하여 최종여과 하였다. 이렇게 얻은 여과액을 다시 4℃의 저온 창고에서 약 10일간 숙성시킨 후 이 액을 다시 0.25μM의 여과기를 이용하여 여과액을 동결건조하여 '장뇌삼 바실러스 발효액' 분말을 얻었다. After washing with purified water and drying, the dried ginseng ginseng was pulverized and made fine using 300 mesh. This was added to a 10 g / L Bacillus culture (Tryptic soy broth, Acumedia, USA). Bacillus subtilis (Bacillus subtilis) was used for fermentation and added at 1,000,000 cfu / L per culture. Cultures were cultured in a 5 L fermenter for 7 days at 37 ° C and pH 5-7. After incubation, the culture broth was vacuum-sterilized at 85 ° C, centrifuged, and the culture was firstly removed, followed by final filtration using 0.25 μM filter paper. The filtrate thus obtained was aged at a low temperature warehouse at 4 ° C for about 10 days, and then the filtrate was lyophilized using a 0.25 μM filter to obtain a 'Chennai ginseng bacillus fermentation broth' powder.
제조예Manufacturing example 1 및 2. 유산균을 이용한 장뇌삼 발효액 제조 1 and 2. Preparation of fermented Ganoderma lucidum using lactic acid bacteria
상기 비교제조예 1 및 2의 '장뇌삼 효모 발효액' 또는 '장뇌삼 바실러스 발효액'의 분말을 5g/L가 되게 유산균 배양액(MRS broth, Difco, 미합중국)에 첨가하였다. 발효에 사용한 유산균 균주는 락토바실러스 플란타룸(Lactobacillus plantarum)을 사용하였으며, 배양액당 1,000,000 cfu/L로 첨가하였다. 배양은 5L 발효조를 이용하여 7일간, 37℃, pH 3 ~ 6로 유지하며 배양하였다. 배양 후 배양액을 85℃에서 진공멸균한 뒤 원심분리하여 배양균을 1차 제거 한 후 0.25 μM 여과지를 이용하여 최종 여과하였다. 이렇게 얻은 여과액을 다시 4℃의 저온 창고에서 약 10일간 숙성시킨 후 이액을 다시 0.25μM의 여과기를 이용하여 여과액을 동결건조하여 '장뇌삼 효모-유산균 발효액'(제조예 1)과 '장뇌삼 바실러스-유산균 발효액'(제조예 2)의 분말을 얻었다. 통상 상기 제조예 1과 제조예 2를 장뇌삼 발효액으로 칭한다. Powder of the 'ginseng yeast fermentation broth' or the 'ginseng extract of Bacillus cereus Bacillus' in Comparative Preparation Examples 1 and 2 was added to a lactic acid bacteria culture solution (MRS broth, Difco, USA) so as to have a concentration of 5 g / L. Lactobacillus plantarum was used as a lactic acid bacteria strain for fermentation and added at 1,000,000 cfu / L per culture. Cultures were cultured in a 5 L fermenter for 7 days at 37 ° C and pH 3 to 6. After incubation, the culture broth was vacuum-sterilized at 85 ° C, centrifuged, and the culture was firstly removed, followed by final filtration using 0.25 μM filter paper. The resulting filtrate was aged for about 10 days at a low temperature warehouse at 4 DEG C and the filtrate was lyophilized by using a 0.25 mu M filter to obtain a solution of 'Jangbyeonggam-yeast-lactic acid fermentation broth' (Preparation Example 1) - > Lactic acid fermentation broth (Preparation Example 2). Generally, the above Production Example 1 and Production Example 2 are referred to as a cinnamon germ fermentation broth.
실험예Experimental Example 1: 장뇌삼 발효액의 1: of ginseng fermentation broth MMPMMP -1 생성 억제 효과-1 production inhibitory effect
상기 제조예 1 및 2, 비교제조예 1 및 2에서 얻은 시료를 이용하여 다음과 같이 실험하였다. 먼저, 인체 정상 섬유아세포를 48-웰 마이크로 플레이트(Nunc, 덴마크)의 각 웰에 1× 106세포가 되도록 접종하고, DMEM 배지(Sigma, 미합중국)에서 37℃에서 24시간 동안 배양하였다. 이어, 제조예 1 및 2 또는 비교제조예 1 및 2의 농도를 각각 0.1% 및 0.5% (중량%)로 하여 무혈청(serum-free) DMEM 배지로 교체한 실험과, 장뇌삼 발효액이 포함되지 않은 무혈청 DMEM 배지로 교체한 대조군을 48시간 동안 추가로 배양하였다.Using the samples obtained in Preparation Examples 1 and 2 and Comparative Preparation Examples 1 and 2, the following experiment was conducted. First, normal human fibroblasts were inoculated into each well of a 48-well microplate (Nunc, Denmark) at 1 × 10 6 cells and cultured in DMEM medium (Sigma, USA) at 37 ° C. for 24 hours. Next, experiments were conducted in which the concentrations of Preparation Examples 1 and 2 or Comparative Preparation Examples 1 and 2 were changed to serum-free DMEM medium at 0.1% and 0.5% (wt%), respectively, The control group, which was replaced with serum-free DMEM medium, was further cultured for 48 hours.
배양 후, 각 웰의 상층액을 모아 MMP-1 분석 킷트(Amersham, 미합중국)를 이용하여 새로 합성된 MMP-1의 양을 측정한 뒤, MMP-1의 양은 ng/㎖ 환산하였다. 양성 대조군으로 TGF-β(10ng/ml, Roche, 미합중국)을 사용하였으며 MMP-1 생성 억제율은 하기 수학식 1에 따라 구하였으며 결과는 표 1에 나타내었다.After the incubation, the supernatant of each well was collected and the amount of newly synthesized MMP-1 was measured using an MMP-1 assay kit (Amersham, USA), and the amount of MMP-1 was converted to ng / ml. TGF-beta (10 ng / ml, Roche, USA) was used as a positive control and the inhibition rate of MMP-1 production was calculated according to the following formula 1.
실험예Experimental Example 2: 장뇌삼 발효액의 콜라겐 합성 증진 효과 2: Enhancement of Collagen Synthesis Effect of Ganoderma lucidum Fermentation Liquid
인체 정상 섬유아세포를 48-웰 마이크로 플레이트의 각 웰에 1 x 106세포가 되도록 접종하고, DMEM 배지에서 37℃에서 24시간 동안 배양하였다. 이어, 제조예 1 및 2, 비교제조예 1 및 2를 각각 최종 농도 0.1 중량% 및 0.5 중량%로 하여 무혈청 DMEM 배지로 교체한 실험군과 장뇌삼 배양액이 포함되지 않은 무혈청 DMEM 배지로 교체한 대조군을 24시간 동안 추가로 배양하였다. 배양 후, 각 웰의 상층액을 모아 프로콜라겐 (procollagen) 타입 I C-펩타이드 (PICP) 양을 키트 (Takara, 일본)를 이용하여 새로 합성된 콜라겐양을 측정하였다. PICP 양은 ng/㎖ 환산하였으며, 양성대조군으로 역시 TGF-β를 사용하였다. 콜라겐 생합성 증가율은 하기 수학식 2에 의해 구하였으며 결과는 표 2에 나타나 있다.Normal human fibroblasts were inoculated into each well of a 48-well microplate to a concentration of 1 x 10 6 cells and cultured in DMEM medium at 37 ° C for 24 hours. Subsequently, the control group in which Production Examples 1 and 2 and Comparative Preparation Examples 1 and 2 were replaced with serum-free DMEM medium at a final concentration of 0.1 wt% and 0.5 wt%, respectively, and a control group in which serum-free DMEM medium containing no cambium- Were further cultured for 24 hours. After culturing, the supernatant of each well was collected and the amount of procollagen type I C-peptide (PICP) was measured using a kit (Takara, Japan). The amount of PICP was converted to ng / ml, and TGF-β was also used as a positive control. The increase rate of collagen biosynthesis was calculated by the following equation (2) and the results are shown in Table 2.
이상의 실험예 1 및 2를 통해, 본 발명에 따른 장뇌삼 발효액이 콜라겐 분해 특징을 갖는 MMP-1의 생합성을 억제해 주고, 콜라겐 합성 촉진 효과가 우수하며, 장뇌삼 바실러스 발효액 및 장뇌삼 효모 발효액에 비해 그 효과가 훨씬 더 우수함을 알 수 있었다.Through the above Experimental Examples 1 and 2, it can be seen that the cambium fermentation broth according to the present invention inhibits the biosynthesis of MMP-1 having collagen degradation characteristics and is excellent in promoting collagen synthesis and has a better effect than the fermentation broth of Camellia Bacillus Was much better.
실험예Experimental Example 3: 장뇌삼 발효액의 섬유아세포 증식 효과 3: Fibroblast proliferation effect of ginseng fermentation broth
인체 정상 섬유아세포를 96-웰 마이크로 플레이트의 각 웰에 1 x 104세포가 되도록 접종하고, DMEM 배지에서 37℃에서 24시간 동안 배양하였다. 이어, 제조예 1 및 2, 비교제조예 1 및 2를 각각 최종 농도 0.1 중량%, 0.5 중량%로 하여 혈청이 2.5 중량% 함유되어 있는 DMEM 배지로 교체한 실험군과 장뇌삼 발효액이 포함되지 않은 무혈청 DMEM 배지로 교체한 대조군을 24시간 동안 추가로 배양하였다. 배양 후, 세포의 생존율을 비교하기 위하여 MTT(시그마, 미합중국) 솔루션(3mg/ml)을 첨가하여 세포 생존율을 ELISA READER(Molecular Devices, 미합중국)를 이용하여 570nm에서 흡광도를 측정하고 하기 수학식 3에 따라 세포 생존율(%)을 계산하였으며 실험 결과는 하기 표 3에 기재하였다. Normal human fibroblasts were inoculated into each well of a 96-well microplate to a concentration of 1 x 10 4 cells and cultured in DMEM medium at 37 ° C for 24 hours. Then, in Experimental Examples 1 and 2 and Comparative Preparation Examples 1 and 2, the experimental group was changed to a DMEM medium containing 2.5% by weight of serum with a final concentration of 0.1% by weight and 0.5% by weight, respectively, The control group, which was replaced with DMEM medium, was further cultured for 24 hours. After incubation, MTT (Sigma, USA) solution (3 mg / ml) was added to compare the cell viability and the cell viability was measured at 570 nm using an ELISA reader (Molecular Devices, USA) The cell viability (%) was calculated according to the following table.
상기 실험 결과를 통해, 본 발명에 따른 장뇌삼 발효액이 장뇌삼 효모 발효액 및 장뇌삼 바실러스 발효액에 비해 세포 생성 증가율이 훨씬 뛰어났으며, 양성 대조군인 TGF-β와 유사하거나 훨씬 우수한 세포 생성 증가율을 보임을 알 수 있었다.From the above experimental results, it can be seen that the cambium fermentation broth according to the present invention has a much higher cell growth rate than the fermentation broth of camphor brewer's yeast and camellia Bacillus and exhibits a similar or even better cell growth rate to that of the positive control, TGF-β there was.
실험예Experimental Example 4. 장뇌삼 발효액의 락트산에 의한 세포자극 완화 효과 시험 4. Effect of Lactic Acid on Cell Stimulation in Changb
인간 피부 세포인 섬유아세포(한국 세포주 은행, 대한민국)를 T-75 플라스크(Falcon, 미합중국)에서 80% 정도 성장할 때까지 배양하였다. 이것을 다시 96-웰 플레이트(Falcon, 미합중국)에 3× 104 cells/well이 되게 옮겨 24시간 배양하였다. 배양 후 현미경을 통해 세포가 완전히 부착되어 잘 자라는지 여부를 확인하고 피부세포 자극원으로 락트산을 이용하여 실험을 진행하였다. 이때 락트산은 0.2 중량%를 사용하였다. 즉, 96웰의 각각에 0.2 중량% 락트산이 함유된 DMEM(시그마, 미합중국) 배지를 200㎕씩 첨가하고 제조예 1 및 2, 비교제조예 1 및 2를 각각 0.1 및 0.5 중량%로 조절하여 첨가하였다. 이때 락트산 및 장뇌삼 발효액을 첨가하지 않은 것을 대조군으로 하였고, 락트산만 첨가한 것을 비교군으로 하였다. 시험물질을 첨가하고 12시간 경과 후 세포의 생존율을 비교하기 위하여 MTT(시그마, 미합중국) 솔루션(3mg/ml)을 첨가하여 세포 생존율을 ELISA READER(Molecular Devices, 미합중국)를 이용하여 570nm에서 흡광도를 측정하고 하기 수학식 4에 따라 세포 생존율(%)을 계산하였으며 실험 결과는 하기 표 4에 기재하였다.Human fibroblasts (Korean Cell Line Bank, Korea) were cultured in T-75 flasks (Falcon, USA) until they grew to about 80%. The cells were transferred to 96-well plates (Falcon, USA) at 3 × 10 4 cells / well and cultured for 24 hours. After culturing, cells were completely adhered to each other through a microscope to confirm whether they were growing well. Experiments were conducted using lactic acid as a skin cell stimulating agent. At this time, 0.2 wt% of lactic acid was used. That is, 200 쨉 l of DMEM (Sigma, USA) medium containing 0.2% by weight lactic acid was added to each of 96 wells, and Preparation Examples 1 and 2 and Comparative Preparations 1 and 2 were adjusted to 0.1 and 0.5 wt% Respectively. At this time, no lactic acid and camellia fermentation broth added were used as a control group, and only lactic acid supplemented group was used as a comparative group. MTT (Sigma, USA) solution (3 mg / ml) was added to compare cell survival rates after 12 hours of addition of the test substance, and the cell viability was measured at 570 nm using an ELISA reader (Molecular Devices, And cell viability (%) was calculated according to the following equation (4). The experimental results are shown in Table 4 below.
상기 결과를 통해, 장뇌삼 발효액을 처리한 경우는 락트산 처리에 의한 세포생성 억제를 완화시켜주어 세포 생성을 크게 증가시켰으며, 장뇌삼 효모 발효액 및 장뇌삼 바실러스 발효액 에 비해 세포 생성 증가율이 훨씬 뛰어남을 알 수 있었다.From the above results, it was found that the treatment of cambium fermentation broth significantly inhibited the cell formation by lactic acid treatment, greatly increased the cell production, and the cell growth rate was much better than that of the fermentation broth of camphor brewer's yeast and Camellia sinensis Bacillus .
실험예 5: 장뇌삼 발효 추출물의 B16F1 멜라닌형성세포를 이용한 멜라닌 생성 억제효과 Experimental Example 5: Effect of fermented extract of cinnamon gum on inhibition of melanin formation using B16F1 melanin-forming cells
본 실험예 5는 상기 장뇌삼 발효액의 미백 효과를 확인하기 위해 B16F1 멜라닌 형성 세포에 대한 멜라닌 생성 억제 정도를 보고 미백 효과를 판단한 것이다. 본 실험예 3에 사용된 B16F1 멜라닌 형성 세포는 마우스에서 유래한 세포균주이며, 멜라닌이라는 흑색 색소를 분비하는 세포이다. 이 세포의 인공 배양 중에 시료를 처리하여 멜라닌 흑색 색소가 감소하는 정도를 비교 평가하였다. 본 실험예에 사용된 B16F1 멜라닌 형성 세포는 ATCC(American Type Culture Collection)로부터 분양받아 사용하였다. Experimental Example 5 was performed to determine the whitening effect of B16F1 melanocyte-forming cells in order to examine the whitening effect of the fermentation broth. The B16F1 melanin-forming cell used in Experimental Example 3 is a cell strain derived from a mouse, and is a cell that secretes a melanin pigment called melanin. During the artificial culture of these cells, samples were treated to compare the degree of reduction of melanin pigment. The B16F1 melanin-forming cells used in this experiment were purchased from the American Type Culture Collection (ATCC).
B16F1 멜라닌 형성 세포의 멜라닌 생합성 억제 효과 측정은 다음과 같이 행하였다. B16F1 멜라닌 형성 세포를 6웰 플레이트에 각 웰당 2 X 105 농도로 분주하고 세포를 부착시킨 후 독성을 유발하지 않는 농도로 제조예 1 및 2, 비교제조예 1 및 2를 처리하여 72시간 동안 배양하였다. 72시간 배양 후 세포를 트립신-EDTA로 떼어낸 후 세포수를 측정한 다음 원심분리하여 세포를 회수하였다. 세포 내 멜라닌의 정량은 로탄(Lotan: Cancer Res., 40: 3345-3350, 1980)의 방법을 약간 변형하여 실시하였다. 셀 펠릿을 PBS로 1회 세척한 후 균질화 버퍼액(50 mM 소듐 포스페이트, pH 6.8, 1% Triton X-100, 2 mM PMSF) 1ml를 첨가하여 5분간 와류하여 세포를 파쇄하였다. 원심분리 (3,000 rpm, 10분)하여 얻은 세포 여액에 1N NaOH(10% DMSO)를 첨가하여 추출된 멜라닌을 용해한 후 마이크로 플레이트 판독기로 405 nm에서 멜라닌의 흡광도를 측정한 다음 멜라닌을 정량하여 시료의 멜라닌 생성 저해율(%)을 측정하였다. B16F1 멜라닌 형성 세포의 멜라닌 생성 저해율을 (%)은 하기 수학식 5에 의하여 계산하였으며, 그 결과를 표 5에 기재하였다.Melanin biosynthesis inhibitory effect of B16F1 melanin-forming cells was measured as follows. B16F1 melanogenesis cells were divided into 6 well plates at a concentration of 2 X 10 5 per well and treated with Preparation 1 and 2 and Comparative Preparations 1 and 2 at a concentration that did not induce toxicity after the cells were attached and incubated for 72 hours Respectively. After incubation for 72 hours, the cells were detached with trypsin-EDTA, the number of cells was measured, and the cells were recovered by centrifugation. Quantification of intracellular melanin was carried out with a slight modification of the method of Lotan (Cancer Res., 40: 3345-3350, 1980). Cell pellet was washed once with PBS, and 1 ml of homogenization buffer solution (50 mM sodium phosphate, pH 6.8, 1% Triton X-100, 2 mM PMSF) was added and vortexed for 5 minutes to disrupt the cells. After centrifugation (3,000 rpm, 10 min), 1N NaOH (10% DMSO) was added to the cell filtrate to dissolve the extracted melanin and the absorbance of melanin was measured at 405 nm with a microplate reader. The inhibition rate (%) of melanin formation was measured. Melanin formation inhibition rate (%) of B16F1 melanin-forming cells was calculated by the following formula (5), and the results are shown in Table 5.
A : 시료를 첨가하지 않은 웰의 멜라닌 양A: Amount of melanin in wells to which no sample was added
B : 시료를 첨가한 웰의 멜라닌 양B: Amount of melanin in the well to which the sample was added
(중량%)Treatment concentration
(weight%)
상기 표 5의 결과에서 알 수 있듯이, 본 발명의 제조예 1 내지 2에 의해 제조된 장뇌삼 발효액은 B16F1 멜라닌 형성 세포에서 멜라닌 생성을 크게 저해했으며 비교 제조예 1 또는 2의 멜라닌 생성 저해 효과와 비교하여 우수하다는 것을 확인할 수 있었다. As can be seen from the results of Table 5, the fermentation broth of the cinnamon produced by Production Examples 1 and 2 of the present invention significantly inhibited melanogenesis in B16F1 melanin-forming cells, and compared with the inhibitory effect of melanin production of Comparative Preparation Example 1 or 2 And it was confirmed that it was excellent.
제형예 1 :장뇌삼 발효액을 함유하는 화장료 조성물의 제조Formulation Example 1: Preparation of a cosmetic composition containing a fermentation broth of cinnamon ginseng
장뇌삼 발효액을 포함하는 화장료는 제조예 1 및 2의 장뇌삼 발효액 포함하는 화장료 조성물(제형예 1 및 2)을 제조하였으며, 효능의 비교를 위해 장뇌삼 발효액 대신에 비교제조예 1의 장뇌삼 효모 발효액을 포함하는 화장료 조성물(비교제형예 1), 장뇌삼 발효액 대신에 보습제로서 글리세린 및 1,3-부틸렌글리콜을 포함하는 화장료 조성물(비교제형예 2), 장뇌삼 발효액 대신에 주름개선 원료로서 아데노신을 포함하는 화장료 조성물(비교제형예 3), 장뇌삼 발효액이나 보습제를 모두 포함하지 않는 화장료 조성물(비교제형예 4)을 하기 표 6에 나타내었다.The cosmetic compositions containing the camellia fermentation broth of Preparation Examples 1 and 2 were prepared as cosmetic compositions (Formulation Examples 1 and 2) containing the fermentation broth of camellia ginseng. In order to compare the efficacy, (Comparative Formulation Example 1), a cosmetic composition comprising glycerin and 1,3-butylene glycol as a moisturizing agent (Comparative Formulation Example 2) instead of a cinnamon fermentation broth, a cosmetic composition containing adenosine as a wrinkle reducing raw material (Comparative Formulation Example 3), and a cosmetic composition (Comparative Formulation Example 4) that does not contain all of the ginseng fermentation broth and moisturizer are shown in Table 6 below.
A
(제조예 1)Ginseng fermentation broth
(Production Example 1)
(비교제조예 1)Fermented juice
(Comparative Production Example 1)
B
실험예Experimental Example 6: 장뇌삼 발효액의 보습 효과 6: Moisturizing effect of Ganoderma lucidum fermentation broth
상기 제형예 1의 화장료 조성물에 대한 임상 보습 효과를 다음과 같이 측정하였다. 설문 조사를 통하여 피부가 건조하다고 느끼는 건강한 성인 남녀 100 명을 무작위로 25 명씩 4개 그룹 (A, B, C 및 D)으로 나눈 후, A그룹에는 제형예 1의 화장료 조성물을, B그룹에는 비교제형예 1의 화장료 조성물을, C 그룹에는 비교제형예 2의 화장료 조성물을, D 비교제형예 4의 화장료 조성물을 각각 1일 2회씩 8주간 안면에 도포하게 하였다. 보습 효과는 실사용 시험 시작 후부터 매 2주간, 그리고 종료 후의 개선 효과를 Corneometer CM 820 (Corage +Khazaka, Germany)를 이용하여 평가하였다. 실험 결과는 하기 표 7에 나타내었다.The clinical moisturizing effect of the cosmetic composition of Formulation Example 1 was measured as follows. 100 healthy adults and women who feel dry skin were divided randomly into four groups (A, B, C and D) by 25 persons, and the cosmetic composition of Formulation Example 1 was compared to the composition of Group A The cosmetic composition of Formulation Example 1, the cosmetic composition of Comparative Formulation Example 2, and the cosmetic composition of D Comparative Formulation 4 were applied to the face for 2 weeks, twice a day for 8 weeks. The moisturizing effect was evaluated by Corneometer CM 820 (Corage + Khazaka, Germany) for every 2 weeks and after the start of the test. The experimental results are shown in Table 7 below.
상기 표 7에 나타낸 바와 같이, 일반 다른 보습제를 함유한 화장료(비교제형예 2)와 비교하여도 본 발명의 장뇌삼 발효액 함유한 화장료(제형예 1)의 보습효과가 우수함을 확인할 수 있었다.As shown in Table 7, it was confirmed that the moisturizing effect of the cosmetic composition (Formulation Example 1) containing the fermented ginseng fermented broth of the present invention of the present invention is superior to the cosmetic composition containing the other moisturizing agents (Comparative Formulation Example 2).
실험예 7. 장뇌삼 발효액의 피부 주름 개선효과Experimental Example 7. Improvement of Skin Wrinkle of Root Bran Ginseng Fermentation Solution
본 발명의 장뇌삼 발효액을 함유하는 화장료의 피부 주름 개선효과에 대한 임상실험을 실시하였다. 임상시험은 각 화장료의 실제 사용 테스트를 통하여 평가하였다. 즉, 임상실험은 40-60세 여성 100 명을 무작위로 25 명씩 4개 그룹 (A, B, C 및 D)으로 나눈 후, A그룹에는 제형예 1의 화장료 조성물을, B그룹에는 비교제형예 1의 화장료 조성물을, C그룹에는 비교제형예 2의 화장료 조성물을, D 비교제형예 3의 화장료 조성물을 각각 1일 2회씩 8주간 안면에 도포하게 하였다. 8주 후의 주름 개선 효과를 육안으로 평가하여 주름 개선 정도를 확인하였다. 이 평가를 토대한 주름 개선 효과 결과는 하기의 표 8에 나타내었다. Clinical trials were conducted on the effect of the cosmetic composition containing the fermentation broth of camellia ginseng according to the present invention on the skin wrinkles. Clinical trials were conducted through actual use tests of each cosmetic product. That is, in a clinical experiment, 100 female 40-60 year-olds were randomly divided into four groups (A, B, C and D) by 25 persons. The cosmetic composition of Formulation Example 1 was applied to Group A, 1, the cosmetic composition of Comparative Formulation Example 2, and the cosmetic composition of Comparative Composition D 3 were applied to the face in the face for 8 weeks twice a day, respectively. The wrinkle improvement effect after 8 weeks was visually evaluated to confirm the wrinkle improvement degree. The results of the wrinkle-improving effect based on this evaluation are shown in Table 8 below.
실험 완료 후 피부 주름 개선 효과는 제품 사용 전과 3개월간 사용 후의 각 피검자의 주름 개선 효과를 숙련된 의사의 육안 관찰 및 기기측정(cutometer SEM 575, C+K Electronic Co.,Germany)을 통하여 평가하였으며, 실험 결과는 하기의 표 8에 나타낸 바와 같다.The effect of improving wrinkles after the completion of the experiment was evaluated by visual examination and instrument measurement (cutometer SEM 575, C + K Electronic Co., Germany) of a skilled physician before and after 3 months of use. The experimental results are shown in Table 8 below.
상기 표 8의 결과에서도 알 수 있듯이, 본 발명의 장뇌삼 발효액을 함유한 제형예 1 의 장뇌삼 효모 발효액을 함유하는 비교제형예 1에 비하여 약 1.9배 높은 주름개선 효과를 보여주었다. 또한, 장뇌삼 발효액 대신 주름 개선 효과가 있는 것으로 알려진 아데노신을 함유하는 비교 제형예 3의 화장료와 유사한 결과가 나타나, 장뇌삼 발효액이 우수한 주름 개선 효과를 나타냄을 알 수 있었다. As can be seen from the results of Table 8, the wrinkle-improving effect was about 1.9 times higher than that of Comparative Formulation Example 1 containing the fermentation broth of Form 1 of formulation 1 containing the fermentation broth of cambium of the present invention. In addition, similar results were obtained with the cosmetic preparation of Comparative Example 3 containing adenosine, which is known to have a wrinkle-improving effect instead of the camphor ginseng fermentation broth, indicating that the camellia fermentation broth exhibits excellent wrinkle-improving effect.
실험예Experimental Example 8: 피부 탄력 개선 효과 측정 8: Measurement of skin elasticity improvement effect
본 실험예 8은 제조예 1에서 수득한 장뇌삼 발효액을 포함하는 제형예 1 및 비교제형예에 따른 화장료 조성물의 피부 탄력 개선 효과를 알아보기 위하여, 30~40대의 탄력이 감소한 여성 30명을 대상으로 측정하였다. 10명씩 A, B, C의 4그룹으로 나눈 뒤, A 그룹에는 제형예 1을, B그룹에는 비교제형예 1를, C그룹에는 비교 제형예 4를 안면에 매일 아침, 저녁으로 2회씩 12주간 도포하게 한 후, 12주 후 피부 탄력을 측정하였다. 얼굴 부위의 탄력을 cutometer SEM575 (MPA 580, Courage+Khazaka GmbH, Germany)를 이용하여 측정하였으며, 피부 탄력을 나타내는 R2(biological elasticity)를 도포 전과 도포 후를 측정한 뒤 개선도(%)로 평가하였다. 그 결과는 하기 표 9에 나타내었으며, 결과는 각 군에 대한 개선도의 평균치이다.In Experimental Example 8, to evaluate the skin elasticity improvement effect of the cosmetic composition according to Formulation Example 1 and Comparative Formulation Example containing the fermented solution of cinnamon ginseng obtained in Preparation Example 1, 30 women with 30 to 40 elasticity decreased Respectively. 10 groups were divided into 4 groups of A, B, and C, followed by Formulation Example 1 for Group A, Comparative Formulation Example 1 for Group B, and Comparative Formulation Example 4 for Group C for 12 weeks The skin elasticity was measured after 12 weeks. The elasticity of the facial region was measured using a cutometer SEM575 (MPA 580, Courage + Khazaka GmbH, Germany), and the R2 (biological elasticity) indicating skin elasticity was measured before and after application . The results are shown in Table 9 below, and the results are an average value of improvement for each group.
상기 표 8에 나타난 바와 같이, 장뇌삼 발효 추출물이 함유된 제형예 1은 비교제형예 1 또는 4에 비하여 피부 탄력이 매우 향상됨을 알 수 있었다.As shown in Table 8, Formulation Example 1 containing the fermented extract of Camellia sinensis significantly improved skin elasticity as compared to Comparative Formulation Example 1 or 4.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (8)
The cosmetic composition according to claim 1, wherein the camellia fermentation broth is contained in an amount of 0.0001 to 30.0% by weight based on the total weight of the cosmetic composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160034639A KR101855206B1 (en) | 2016-03-23 | 2016-03-23 | Cosmetic Composition Comprising the Fermented Extract of Panax ginseng |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160034639A KR101855206B1 (en) | 2016-03-23 | 2016-03-23 | Cosmetic Composition Comprising the Fermented Extract of Panax ginseng |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170110358A KR20170110358A (en) | 2017-10-11 |
| KR101855206B1 true KR101855206B1 (en) | 2018-05-09 |
Family
ID=60139168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160034639A Active KR101855206B1 (en) | 2016-03-23 | 2016-03-23 | Cosmetic Composition Comprising the Fermented Extract of Panax ginseng |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101855206B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110680774B (en) * | 2019-10-28 | 2022-07-01 | 上海仪玳化妆品有限公司 | Preparation method of jasmine double-bacterium fermented cosmetic and application of product |
| CN110680781B (en) * | 2019-10-28 | 2022-07-05 | 上海仪玳化妆品有限公司 | White peony root fermented cosmetic and preparation method and application thereof |
| CN111528458A (en) * | 2020-03-23 | 2020-08-14 | 广州正明生物科技有限公司 | Functional raw material obtained by fermenting flowers and fruits in stages based on saccharomycetes and lactobacillus plantarum and application of functional raw material |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101238968B1 (en) * | 2012-04-24 | 2013-03-04 | 최재홍 | Method for preparing composition comprising fermented wild ginseng that contain ergothioneine |
-
2016
- 2016-03-23 KR KR1020160034639A patent/KR101855206B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101238968B1 (en) * | 2012-04-24 | 2013-03-04 | 최재홍 | Method for preparing composition comprising fermented wild ginseng that contain ergothioneine |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170110358A (en) | 2017-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101885195B1 (en) | Cosmetic Composition with Fermentative Extract of Osmanthus fragrans | |
| KR101716428B1 (en) | Cosmetic composition containing fermentative extract of hippocampus coronatus as active ingredient | |
| KR101768026B1 (en) | Cosmetic Composition for Improving Skin Wrinkle Comprising the Fermented Extract of Morinda citrifolia as Active Ingredient | |
| KR101902988B1 (en) | Cosmetic composition comprising the extract of cacao nibs irradiated with far-infrared ray and steamed | |
| KR20110122448A (en) | Cosmetic composition containing gelatin paste extract as an active ingredient | |
| KR101645476B1 (en) | Cosmetic Composition containing Fermentative Extract of Hippophae rhamnoides with Increased Amount of Vitamin C Fermented by Aureobasidium pullulans | |
| KR101855206B1 (en) | Cosmetic Composition Comprising the Fermented Extract of Panax ginseng | |
| KR101855207B1 (en) | Cosmetic composition containing fermentative extract of terminalia ferdinandiana with increased amount of vitamin c fermented by aureobasidium pullulans | |
| KR101207559B1 (en) | Cosmetic composition comprising the extract of Pourthiaea villosa as active ingredient | |
| KR102247965B1 (en) | Cosmetic Composition for Whitening of the Skin Comprising the Extract of Fermented Zea Mays Silk | |
| KR102010235B1 (en) | Cosmetic composition having skin whitening effect | |
| KR101719723B1 (en) | Cosmetic composition comprising the extract of Ensete lasiocarpum as active ingredient | |
| KR20110121775A (en) | Cosmetic composition containing the extract of gold pheasant as an active ingredient | |
| KR20110119316A (en) | Cosmetic composition containing saponflower extract as an active ingredient | |
| KR20110105243A (en) | Cosmetic composition for skin whitening comprising mung bean fermentation-enzyme extract | |
| KR20180042541A (en) | Cosmetic composition comprising the very high-pressure extract of narcissus tazetta bulb fermentation | |
| KR101775485B1 (en) | Cosmetic composition containing fermentative extract of Spatholobus suberectus Dunn as active ingredient | |
| KR101843976B1 (en) | Cosmetic composition comprising extract of geminated phaseolus radiatus fermented by aureobasidium pullulans | |
| KR20160087507A (en) | cosmetic composition containing Phaseolus Radiatus Seed, Phaseolus Vulgaris (Kidney Bean) Seed and Black Soybean extracts by fermentation and enzyme treatment | |
| KR20140071716A (en) | Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent | |
| KR20190048935A (en) | Cosmetic composition comprising extract of red onion fermented by aureobasidium pullulans | |
| KR20110117471A (en) | Cosmetic composition for skin whitening containing yeast tree fermentation broth | |
| KR101207560B1 (en) | Cosmetic composition comprising the extract of Cleyera japonica as active ingredient | |
| KR102064602B1 (en) | Cosmetic Composition for Whitening of the Skin Comprising the Extract of Fermented Perna Canaliculus | |
| KR20210045667A (en) | Cosmetic Composition for Whitening Skin Comprising Extract of Fermented Philodendron bipinnatifidum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20160323 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170322 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170830 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20180416 |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180430 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20180502 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20210329 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220413 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230314 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240319 Start annual number: 7 End annual number: 7 |